Immunotherapy, a revolutionary approach in the treatment of cancer and other diseases, has significantly transformed the landscape of modern healthcare. This therapy exploits the body's immune system to fight disease, offering a potent alternative to conventional treatments. This article provides an in-depth understanding of immunotherapy for physicians, facilitating better patient care and treatment outcomes.
Immunotherapy, also known as biotherapy, involves the use of the body's immune system to combat diseases. It can be categorized into two types: active and passive. Active immunotherapy stimulates the immune system to attack disease cells, while passive immunotherapy involves the administration of synthetic immune system proteins.
Immunotherapy has revolutionized cancer treatment by offering alternatives when traditional treatments are ineffective or too aggressive. It can be used alone or in combination with other treatments. Checkpoint inhibitors, CAR-T cell therapy, and therapeutic vaccines are some of the most commonly used types of immunotherapy in oncology.
Recent advancements in immunotherapy include the development of bispecific antibodies, oncolytic virus therapy, and tumor infiltrating lymphocytes (TIL) therapy. These innovations have shown promising results in the treatment of various types of cancer, including melanoma, lung, and breast cancer.
Despite its potential, immunotherapy faces several challenges, including the unpredictability of immune responses and severe side effects. However, ongoing research and technological advancements are expected to address these issues and expand its applicability.
Immunotherapy is a crucial component of modern healthcare, offering hope for better treatment outcomes in various diseases, particularly cancer. As physicians, staying abreast of the latest developments in this field is essential to deliver optimal patient care. Despite the challenges, the future of immunotherapy looks promising with continuous research and innovations.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation